KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Abbott Laboratories (ABT) EBIAT (2016 - 2025)

Abbott Laboratories (ABT) has disclosed EBIAT for 17 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • Quarterly EBIAT fell 80.76% to $1.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 billion through Dec 2025, down 51.32% year-over-year, with the annual reading at $6.5 billion for FY2025, 51.32% down from the prior year.
  • EBIAT hit $1.8 billion in Q4 2025 for Abbott Laboratories, up from $1.6 billion in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $9.2 billion in Q4 2024 to a low of $1.0 billion in Q4 2022.
  • Historically, EBIAT has averaged $2.0 billion across 5 years, with a median of $1.6 billion in 2023.
  • Biggest five-year swings in EBIAT: soared 478.98% in 2024 and later crashed 80.76% in 2025.
  • Year by year, EBIAT stood at $2.0 billion in 2021, then crashed by 48.06% to $1.0 billion in 2022, then soared by 54.31% to $1.6 billion in 2023, then skyrocketed by 478.98% to $9.2 billion in 2024, then plummeted by 80.76% to $1.8 billion in 2025.
  • Business Quant data shows EBIAT for ABT at $1.8 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.8 billion in Q2 2025.